The 3 ϩ 3 design is the most common choice among clinicians for phase I dose-escalation oncology trials. In recent reviews, more than 95% of phase I trials have been based on the 3 ϩ 3 design. Given that it is intuitive and its implementation does not require a computer program, clinicians can conduct 3 ϩ 3 dose escalations in practice with virtually no logistic cost, and trial protocols based on the 3 ϩ 3 design pass institutional review board and biostatistics reviews quickly. However, the performance of the 3 ϩ 3 design has rarely been compared with model-based designs in simulation studies with matched sample sizes. In the vast majority of statistical literature, the 3 ϩ 3 design has been shown to be inferior in identifying true maximum-tolerated doses (MTDs), although the sample size required by the 3 ϩ 3 design is often orders-of-magnitude smaller than model-based designs. In this article, through comparative simulation studies with matched sample sizes, we demonstrate that the 3 ϩ 3 design has higher risks of exposing patients to toxic doses above the MTD than the modified toxicity probability interval (mTPI) design, a newly developed adaptive method. In addition, compared with the mTPI design, the 3 ϩ 3 design does not yield higher probabilities in identifying the correct MTD, even when the sample size is matched. Given that the mTPI design is equally transparent, costless to implement with free software, and more flexible in practical situations, we highly encourage its adoption in early dose-escalation studies whenever the 3 ϩ 3 design is also considered. We provide free software to allow direct comparisons of the 3 ϩ 3 design with other model-based designs in simulation studies with matched sample sizes.
INTRODUCTION
A phase I oncology trial aims to determine the maximum-tolerated dose (MTD) of a drug-the highest dose with a toxicity rate close to a prespecified target level, p T . The 3 ϩ 3 design 1,2 is the leading method for phase I dose-escalation trials in oncology; over 95% of published phase I trials in the past two decades have been based on this design. [3] [4] [5] The popularity of the 3 ϩ 3 design is striking, because numerous model-based dose-escalation methods have been developed by biostatisticians during the same time period, and almost all of the new methods seem to exhibit better performance than the 3 ϩ 3 design. [6] [7] [8] [9] The main reason for the popularity of the 3 ϩ 3 design results from its simplicity (no computer program is required), transparency, and costless implementation in practice. In contrast, most modelbased designs often require considerable logistic burden and complexity to implement. Even if the practical burden could be overcome, protocols based on model-based designs are often subject to more thorough reviews by institutional review boards or among biostatisticians, because these new designs require computer-generated operating characteristics. Conversely, if a protocol is based on the 3 ϩ 3 design, this requirement disappears, because the design has been widely used. As a result, despite the acceleration in the development of adaptive model-based designs, the lower standard in the review process and cost-free implementation in practice makes the 3 ϩ 3 design persistently popular among physicians. Setting aside logistic issues, we seek to assess the advantages of model-based designs over the 3 ϩ 3 design. In reviewing the statistical literature on phase I adaptive designs compared with the 3 ϩ 3 design, we found that most studies did not match sample sizes across the designs. For example, Ji et al 10 showed that 3 ϩ 3 design exhibited a smaller average sample size in computer simulations than model-based designs, and consequently, the 3 ϩ 3 design also identified the true MTD a smaller percentage of the time. Because sample size was not matched in the comparison, it is difficult to determine the reason for the reduced percentages under the 3 ϩ 3 design. More importantly, because phase I trials focus on patient safety, comparisons without matching sample sizes cannot provide accurate assessments of the safety characteristics of designs. In fact, designs resulting in larger sample sizes are usually safer, because patients enrolled onto trials during the latter stages will be better protected as a result of more-precise statistical inference.
In this article, we report a comprehensive simulation study to evaluate the operating characteristics of the 3 ϩ 3 design and a newly developed adaptive design known as the modified toxicity probability interval (mTPI) method. 5, 10 In doing so, we match the sample size of both designs. Compared with the 3 ϩ 3 design, the mTPI design is equally as simple, transparent, and costless to implement. In other words, the logistic burden of both designs is negligible, allowing us to focus on the simulation performance. Although the mTPI design is a novel approach, it has already received attention from both research and industry entities.
11,12
For example, almost all phase I oncology trials conducted at Merck (Whitehouse Station, NJ) in the past 2 years have been based on the mTPI design or its variations (K. Anderson, personal communication, June 2012). Recently, phase I trials based on the mTPI design have been published in the clinical community.
13,14 Considering the short time period since the publication of the mTPI design, this popularity is encouraging.
The 3 ϩ 3 design consists of a set of deterministic rules that dictate dose-escalation decisions based on observed patient outcomes (Fig 1) . For example, if zero, one, or Ͼ one toxicities are observed in three treated patients, the 3 ϩ 3 design will recommend escalating the dose level, continuing at the same dose level, or de-escalating the dose level, respectively (as described by Ibrahim et al 15 and Strumberg et al 16 ). The mTPI design uses a Bayesian statistical framework and a beta/binomial hierarchic model to compute the posterior probabilities of three intervals that reflect the relative distance between the toxicity rate of each dose level to the target probability, p T . That is, the mTPI design replaces the 3 ϩ 3 rules that are based on events such as zero of three, one of three, two of three, and three of three with a model-based inference on the toxicity probability intervals. For example, for each of the three p T values, the mTPI design can be applied to three corresponding dosing intervals listed in Table 1 (ie, underdosing, proper dosing, and overdosing). Ji et al 10 describe the proper dosing interval as the equivalence interval (EI).
Dose-escalation decisions are easily made based on the three dosing intervals. If the toxicity rate of the currently used dose level is within the underdosing interval, the mTPI design will recommend escalating the dose level; in the case of proper dosing, the design will recommend continuing at the current dose; for overdosing, the mTPI design will recommend de-escalating the dose level. These rules are conceptually similar to those used in the 3 ϩ 3 design; however, the decisions of the mTPI design are based on posterior probabilities calculated under a coherent probability model. As a model-based design, the mTPI design automatically and appropriately tailors doseescalation decisions for different trials with different toxicity parameters. More importantly, all the dose-escalation decisions for a given trial can be precalculated under the mTPI design and presented in a two-way table (Fig 2) . Once the trial starts, clinicians can easily monitor the trial and select the appropriate doses following the precalculated table. A hypothetical example is presented in Table 2 . The simplicity and transparency of the mTPI design make it a strong Fig 2. Dose-finding spreadsheet of the modified toxicity probability interval (mTPI) method. The spreadsheet is generated based on a beta/binomial model and precalculated before a trial starts. The letters in different colors are computed based on the decision rules under the mTPI method and represent different dose-finding actions. In addition to actions de-escalate the dose (D), stay at the same dose (S), and escalate the dose (E), the table includes action unacceptable toxicity (U), which is defined as the execution of the dose-exclusion rule in mTPI. MTD, maximum-tolerated dose. 
3. Bold font indicates current dose level being used. Abbreviations: D, de-escalation; DLT, dose-limiting toxicity; E, escalation; MTD, maximum-tolerated dose; mTPI, modified toxicity probability interval; S, stay at same dose.
‫ء‬
Final estimated MTD. †"1 ϩ 0" DLTs among "3 ϩ 3" patients means that there were two cohorts for that dose, and results are one DLT among three patients for the first cohort and zero DLTs among three patients for the second cohort. Therefore, the overall result is one DLT among six patients, used to reach the decision E.
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؉ AND MTPI DESIGNS

Algorithmic and Model-Based Designs
Algorithmic designs such as the 3 ϩ 3 design are based on predetermined and fixed rules. They rely on heuristic reasoning and argument rather than rigorous mathematic modeling. Typically, an algorithmic design has limited generality, because the heuristic argument is often based on strong assumptions. For example, the 3 ϩ 3 design assumes that the target toxicity probability p T takes values close to either one of six or one of three. In contrast, model-based designs such as the mTPI design use quantitative models to describe and account for the uncertainties in the observed data. The models are usually general, allowing the designs to be applied in a variety of cases. More importantly, medical decisions are based on principled mathematic inference, reducing the level of subjectivity in the decision-making process.
؉ Design
We provide a comprehensive and improved algorithm for implementing the 3 ϩ 3 design in practice (Fig 1; full algorithm provided in the Appendix, online only). With this enhanced version of the 3 ϩ 3 design, many important steps (eg, those described in Lin and Shih 17 ) are often ignored in real-life trials. The algorithm indicates that it is necessary to consider at least two variations of the 3 ϩ 3 design, depending on the specifics of the trial. The first variation-the 3 ϩ 3 H design-targets the MTD with Յ two toxicities among six patients (p T Յ two of six); the second variation-the 3 ϩ 3 L design-targets the MTD with Յ one toxicity among six patients (p T Յ one of six). Both MTD definitions are commonly used.
mTPI Design
The full mTPI design is provided in the Appendix (online only) and also described in detail by Ji et al. 10 A trial based on the mTPI design can be monitored using a spreadsheet in the form shown in Figure 2 . The spreadsheet consists of all the dose-escalation rules for a Difference in the average sample size per trial between the 3 ϩ 3 and modified toxicity probability interval designs. Each boxplot summarizes the differences for 14 scenarios for a given target toxicity value p T . 1  2  3  4  5  6  7  8  9  10  11  12  13  14   1  2  3  4  5  6  7  8  9  10  11  12  13  14   1  2  3  4  5  6  7  8  9  10  11  12  13 trial and can be generated using an Excel macro (https://biostatistics. mdanderson.org/SoftwareDownload/SingleSoftware.aspx?Software_ Idϭ72). In Figure 2 , the columns are the numbers of patients treated so far at the current dose level, and the rows are the corresponding numbers of patients experiencing toxicity. The entries of the table are dose-finding decisions-E, S, and D-representing escalating the dose, staying at the same dose, and de-escalating the dose. In addition, decision U means that the current dose level is unacceptable because of high toxicity and should be excluded from the trial. For example, when one of three patients experiences toxicity, the decision can be located at row 1 and column 3, which is S-to stay at the current dose level. This means that the next cohort of patients will be treated at the same dose level currently being used. If zero of three patients experiences toxicity, the decision is at row 0 and column 3, which is E-to escalate. This means that the next cohort of patients will be treated at the next-higher dose level. If three of three patients experiences toxicity, the decision is DU-to de-escalate to the next-lower dose level and exclude the current dose from the trial, because the high toxicity level is unacceptable. Note that these decisions are also in agreement with the 3 ϩ 3 method. However, when different target p T values are used, the decisions in the mTPI table will automatically adjust to the values, which is an advantage of the model-based design over algorithmic approaches.
B A
COMPARISON OF THE 3 ؉ 3 AND MTPI DESIGNS
Simulation Setup
We performed computer simulations of phase I trials based on the 3 ϩ 3 and mTPI designs and compared their operating characteristics. A total of 2,000 trials was simulated for each dose-toxicity scenario using each method.
Values of p T . In practice, the target p T values are rarely larger than 30%, because this implies unnecessary exposure of patients to doses with high toxicity. Here we study three choices of p T : 0.1, 0.2, and 0.3 (ie, the target toxicity rates of the MTD in our simulated trials are 10%, 20%, and 30%). In practice, the specification of p T greatly depends on the disease and the definition of toxicity. For example, for severe diseases and high-risk procedures such as stem-cell transplantation for leukemia, a higher p T value (more tolerance to toxicity) is acceptable, given the high toxicity rate associated with the procedure. In other words, high-grade toxicity events can be tolerated to avoid death. In contrast, in treatment for diseases such as sarcomas or prostate cancer, a lower p T value is specified to impose stricter control of toxicity.
Clinical scenarios. We considered six doses in the simulated trials, with 14 scenarios for each of the three target p T values, resulting in a total of 42 scenarios (Appendix Table A1 and Fig A1, online only) . Details are provided in the Appendix (online only).
Matching sample size. An important feature of our comparison is that we attempted to match the average sample size of the 3 ϩ 3 and mTPI designs for each of the clinical scenarios used in the simulation study. To achieve this, for each scenario, we first applied the 3 ϩ 3 design to 2,000 computer-simulated trials and obtained the mean of the 2,000 sample sizes. We then applied the mTPI design, for which we needed to specify the maximum sample size. The mTPI design stops a trial when the total number of patients enrolled is equal to or larger than the maximum sample size. We calibrated the maximum sample sizes of the mTPI design so that the average sample sizes over simulated trials under both designs were similar across all the scenarios. Figure 3 shows the differences of the average sample sizes (Ͼ 2,000 simulated trials) between the 3ϩ 3 and mTPI designs. The two designs exhibited comparable sample sizes overall. Our calibration of the mTPI design involved only varying the maximum sample size while keeping all the other design features unchanged.
Variations of the 3 ϩ 3 design. To account for different target p T values, we used one of the two 3 ϩ 3 variations (ie, 3 ϩ 3 L and 3 ϩ 3 H designs). These two variations are illustrated in Figure 1 and are also fully described in the Appendix (online only
Performance Evaluation
Summarizing results from 42 scenarios over three different p T values can be subjective, depending on the criteria used in the comparison. Because the average sample sizes between the two methods were roughly matched, we focused our comparison on two summary statistics:
• n Ͼ MTD ϭ mean number of patients treated above the true MTD
• %Sel MTD ϭ percentage of simulated trials selecting the true MTD The value n Ͼ MTD directly evaluates the safety of the design, because under a matched sample size, a smaller n Ͼ MTD value implies less toxicity. The value of %Sel MTD measures the reliability of the design (Appendix Fig A2, online only) . To calculate %Sel MTD , we need Overall toxicity percentages for the 3 ϩ 3 and modified toxicity probability interval (mTPI) designs across all simulated trials. Scenarios in which (A) p T ϭ 0.1, (B) p T ϭ 0.2, and (C) p T ϭ 0.3. The mTPI design represents a safer and more reliable method than the 3 ϩ 3 design for practical phase I trials.
www.jco.org to decide which dose will be considered as the MTD for each scenario. Note that in many scenarios (eg, scenarios five to 11), none of the doses have toxicity probabilities exactly equal to p T . However, some dose-toxicity probabilities are close enough to be declared the MTDs. This is consistent with the real-world belief that the exact value p T is almost never achieved for a dose. To this end, we assumed that any doses with true toxicity probabilities in the EI (p T Ϫ 1 , p T ϩ 2 ) would be considered as the MTDs. In our simulation, we set 1 ϭ 2 ϭ 0.05 so that the EI was (0.05, 0.15) when p T ϭ 0.1, (0.15, 0.25) when p T ϭ 0.2, and (0.25, 0.35) when p T ϭ 0.3. If no dose was in the EI, the highest dose with true toxicity probability Ͻ p T was considered the MTD. If the MTD could not be identified (eg, if all the doses have toxicity probabilities Ͼ p T ), the correct decision was not to select any dose. In that case, the percentage of "none" selection (ie, no dose selected as the MTD) was used to compare the designs. Figure 4 summarizes the comparisons of the 3 ϩ 3 and mTPI designs in terms of safety n Ͼ MTD and reliability %Sel MTD . In Figure 4A , points to the right of 0 correspond to the 3 ϩ 3 design being less safe than the mTPI design; in Figure 4B , points to the left of 0 correspond to the 3 ϩ 3 design being less reliable than the mTPI design. The 3 ϩ 3 design had lowern Ͼ MTD valuesfortwoscenarios,highern Ͼ MTD for34scenarios,and the same n Ͼ MTD for six scenarios. Therefore, in 40 of 42 times, the mTPI design treated fewer or the same number of patients at doses higher than the MTD compared with the 3 ϩ 3 design. Additionally, Figures 5A to 5C examines the overall toxicity percentage, defined as:
Main Results
A/B ϫ 100%, where A ϭ total number of toxicities over all simulated trials, and B ϭ total number of patients treated over all simulated trials
The 3 ϩ 3 design exhibited a lower overall toxicity percentage than the mTPI design in only one of 42 scenarios. Figure 4B compares the reliability measure %Sel MTD between the two designs. In 10 of 42 scenarios, the 3 ϩ 3 design had a higher selection percentage of the true MTD than the mTPI design. Among these scenarios, the 3 ϩ 3 design selected the MTD up to approximately 25% more often than the mTPI design (scenario two for p T ϭ 0.3). In the remaining 32 scenarios, the mTPI design selected the MTD more often than the 3 ϩ 3 design, up to Ͼ 40% (scenario 14 for p T ϭ 0.1). A closer examination revealedthatthe3ϩ3designhadhigher%Sel MTD valuesonlyinscenarios where none of the doses had toxicity probabilities close to p T or where the MTD was at the lower or higher end of the dosing set. We performed additional simulations and confirmed this finding. We found that the 3 ϩ 3 design was a better method when none of the investigational doses was close to the true MTD. This advantage seems to be of limited utility in practice, because doses are usually chosen based on scientific and historical data, and it is anticipated that some of them are close to the MTD, not the opposite.
Summarizing the two plots in Figure 4 and considering that first, the overall sample sizes between the two designs are roughly matched for all the scenarios, and second, the 42 scenarios were constructed to cover a wide range of practical dose-response shapes, we conclude that the 3 ϩ 3 design is more likely to treat patients at toxic doses above the MTD and less likely to identify the true MTD than the mTPI design. In other words, the 3 ϩ 3 design is less safe and less reliable than the mTPI design.
DISCUSSION
The mTPI design has all the attractive properties that the 3 ϩ 3 design enjoys with regard to practical considerations and implementation. Furthermore, compared with the 3 ϩ 3 design, the mTPI design is safer, because it treats fewer patients at doses above the MTD and generally yields higher probabilities in identifying the true MTD.
In practice, a single value n must be provided as the maximum sample size for the mTPI design in any dose-escalation study. In implementing the mTPI design, we recommend a sample size of n ϭ k ϫ (d ϩ 1) to ensure that the design will reach the highest dose if needed and an additional cohort is available for use. Here k is the cohort size, and d is the number of doses. For example, when k ϭ 3 and d ϭ 5, n ϭ 18.
ItiscommonlyacceptedthatphaseItrialsshouldbesmall.However, the consequences of this methodology are poorly addressed in the literature. Small phase I trials often provide suboptimal recommended doses for phase II, resulting in either low efficacy or high toxicity if the recommended doses are too low or too high, respectively. More discussion and investigation of appropriate sample sizes for phase I trials are needed. For example, a streamlined and seamless phase I/II design may result in higher power in the identification of safe and effective doses 18 because of increased sample sizes from the seamless features.
We note that comparisons between the continual reassessment method (CRM) and the 3ϩ 3 design have been investigated by various authors 19-21 and thus are not included in this article. One downside of the CRM is the lack of an easy means of implementation in practice. We have included the CRM design in our software to allow interested users to examine all three designs together (ie, the 3 ϩ 3, CRM, and mTPI designs).
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Appendix Clinical Scenarios Used in the Simulation
In each scenario, true toxicity probabilities are specified for six doses. They are presented in Appendix Table A1 and Fig A1. These scenarios are set up to capture a wide range of dose-response shapes in practice, as discussed previously (Ji Y et al: J Biopharm Stat 22:1206-1219, 2012). Specifically, scenarios one and two represent two cases where all the doses are lower and higher than the maximum-tolerated dose (MTD), respectively; scenarios three and four cover a wide range of toxicities, and one dose is the true MTD with toxicity rate equal to p T ; scenarios five to seven also cover a wide range of toxicities, but the true MTD is bracketed by two adjacent doses; in scenarios eight to 10, toxicity does not vary much and centers around the target p T ; scenarios 11 and 12 are similar to scenarios eight to 10, except doses have a wider range of toxicity; lastly, scenarios 13 and 14 represent two rare cases in which the MTD is the lowest and highest dose, respectively.
Software
We have released free software that allows investigators to conduct the same type of simulations we have described for their own practical trials. The software allows investigators to examine the performance of the 3 ϩ 3 design, modified toxicity probability interval (mTPI) design, and continual reassessment method based on well-matched sample sizes for a variety of scenarios. The software is available at http://www.northshore.org/research/investigators/Yuan-Ji-PhD/.
؉ Design
We summarized various versions of the 3 ϩ 3 design in practice and present a comprehensive and enhanced algorithm. The new 3 ϩ 3 design consists of two variations and is illustrated in Fig 1. The two variations of the 3 ϩ 3 design differ in steps 5b and 5c, when one and two toxicities are observed among six patients, respectively. The algorithm is as follows: ); go to six. 5d. If there are three or four toxicities, declare that the MTD has been exceeded and go to six (it is impossible to have five or six toxicities among six patients at the same dose level under this 3 ϩ 3 design). 6. The MTD has been exceeded.
6a. If the current dose is the lowest dose, stop the trial; declare that the MTD is lower than the lowest dose level. 6b. If the next-lower dose level has six patients, stop the trial and declare that the MTD is the next lower dose level; otherwise, the next-lower dose level has three patients; set the current dose level to be the next-lower dose level and go to two. 7. Escalate if possible.
7a. If the current dose level is the highest dose level; stop the trial and declare that the MTD is higher than the highest dose level. 7b. Otherwise, escalate to the next-higher dose level; go to two.
mTPI Design
To briefly describe the mTPI design, we first introduce some notations for ease of exposition. Let p ϭ (p 1 , …, p d ) denote the toxicity probabilities for doses i ϭ 1, …, d, where d is the total number of candidate doses in the trial. The observed data include n i , the number of patients treated at dose i, and x i , the number of patients experiencing toxicity. The likelihood function for data {(x i , n i ), i ϭ 1, …, d } is a product of binomial densities. The estimates of these toxicity probabilities p are sequentially updated and are used to decide if some of the doses studied would be close to the true MTD.
The mTPI design 10 is an extension of the toxicity probability interval method 5 and employs a simple beta-binomial hierarchic model. Decision rules are based on calculating the unit probability mass (UPM) of three intervals corresponding to underdosing, proper dosing, and overdosing in terms of toxicity. Specifically, the underdosing interval is defined as (0, p T Ϫ 1 ), the overdosing interval as (p T ϩ 2 , 1), and the proper dosing interval as (p T Ϫ 1 , p T ϩ 2 ), where 1 and 2 are small fractions, such as 0.05, to account for the uncertainty around the true target toxicity. A sensitivity analysis reported by Ji et al 10 showed that the mTPI design is robust to the specification of values. In addition, 1 and 2 could take different values to reflect physician preference and the nature of the disease. For advanced diseases with few treatment options, higher toxicity rates might be considered acceptable, implying a specification of 2 Ͼ 1 . For less-advanced diseases, the two values could be identical or 1 could be Ͼ 2 . The three dosing intervals are associated with three different dose-escalation decisions. The underdosing interval corresponds to a dose escalation (E), overdosing corresponds to a dose de-escalation (D), and proper dosing corresponds to staying at the current dose (S). Given an interval and a probability distribution, the UPM of that interval is defined as the probability of the interval divided by the length of the interval. The mTPI design calculates the UPMs for the three dosing intervals, and the one with the largest UPM implies the corresponding dose-finding decision. That decision provides the dose level to be used for future patients. For example, if the underdosing interval has the largest UPM, decision E, to escalate, will be executed, and the next cohort of patients will be treated at the next-higher dose level. Ji et al show that the decision based on the UPM is optimal in that it minimizes a subsequent expected loss. Under the mTPI design, a trial is terminated when either the lowest dose is above the MTD or a prespecified maximum sample size is reached. The article by Ji et al provides more detail. 
Scenarios
